TIBS Launches Its First Incubation in Singapore by Investing US$15M in Tetris Therapeutics to Revolutionize Targeted Cancer Treatments
Together with its affiliates, TIBS has recently made a US$15M seed round investment in Tetris Therapeutics. Tetris Therapeutics, incorporated in March 2022, is a Singapore-based biotechnology company focusing on discovery and development of novel antibody drug conjugate (ADC) therapeutics. Company CEO, Dr. ZOU Bin possesses deep knowledge and experience in drug discovery, operation management and investment; In addition, he is an extremely enthusiastic entrepreneur (ever created two biotechnolog...